^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    LYPD3 expression

    i
    Other names: LYPD3, LY6/PLAUR Domain Containing 3, GPI-Anchored Metastasis-Associated Protein C4.4A Homolog, Ly6/PLAUR Domain-Containing Protein 3, Matrigel-Induced Gene C4 Protein, MIG-C4, GPI-Anchored Metastasis-Associated Protein Homolog
    Entrez ID:
    27076
    7ms
    Comprehensive analysis of exosome gene LYPD3 and prognosis/immune cell infiltration in lung cancer. (PubMed, Transl Cancer Res)
    Additionally, the median half maximal inhibitory concentration (IC50) of bexarotene, cyclopamine, etoposide, and paclitaxel in LYPD3 high group was significantly lower than that in LYPD3 low group. LYPD3 is involved in many BPs of LC, such as regulating immune cell infiltration and affecting prognosis. Therefore, LYPD3 may have potential value as a biomarker for prognosis and immunotherapy in LC.
    Journal • IO biomarker • Immune cell
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • LYPD3 (LY6/PLAUR Domain Containing 3)
    |
    LYPD3 expression
    |
    paclitaxel • etoposide IV • Targretin oral (bexarotene oral) • cyclopamine
    over2years
    LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia. (PubMed, Front Genet)
    This study first proved that the expression of LYPD3 was elevated in AML, which was correlated with poor clinical characteristics and prognosis. In addition, LYPD3 participates in the development of AML through p53 or/and the PI3K/AKT signaling pathway.
    Journal
    |
    LYPD3 (LY6/PLAUR Domain Containing 3)
    |
    LYPD3 expression
    almost3years
    Identification and validation of cellular senescence patterns to predict clinical outcomes and immunotherapeutic responses in lung adenocarcinoma. (PubMed, Cancer Cell Int)
    This study demonstrated the correlations between cellular senescence patterns and tumor immune landscape in LUAD, which enhanced our understanding of the tumor immune microenvironment and provided new insights for improving the outcome of immunotherapy for LUAD patients.
    Clinical • Clinical data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • LYPD3 (LY6/PLAUR Domain Containing 3)
    |
    LYPD3 expression
    |
    MK-2206 • seliciclib (CYC202)